Quadrivas Therapy® to Reduce Lipedema Subcutaneous Adipose Tissue (QUADRIVAS)

Completed · Not applicable

Conditions studied: Lipedema

In brief

Quad Rivas Therapy has been developed by Alyna Eekma from the Netherlands for over thirteen years; anecdotally she has been able to significantly reduce lipedema SAT in women with Stage 1 and 2 lipedema, and can reduce lipedema SAT by 80% in women with Stage 3 lipedema. The study will last for one month, for a total of 12 treatments per subject, seven subjects total, to see if there is a change in percent body fat percentage over the course of these treatments.

Key facts

Study ID

NCT02907411

Run by

University of Arizona

People needed

7

Starts

2016-09-01

Expected to finish

2017-03-18

Last updated by the study team

2017-09-15

Who can join

Age: 19 and older, up to 70. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Ambulatory females of any race able to understand the consent process.
• 19-70 years of age.
• Diagnosis of lipedema Stage 1 or Stage 2 although early Stage 3 will be considered.
• Weight stable for past three months per personal report of the subject.
• Must be able to attend all 12 treatments and pre and post procedures

You may not qualify if…

• Use of medications that might cause weight gain and prevent fat loss (e.g., second generation anti-psychotics, corticosteroids).
• Current use of weight loss medications.
• Tobacco or marijuana use which may alter inflammation in the body.
• Pregnancy due to the risks associated with deep tissue treatment.
• Two or more alcoholic beverages per day, chronically.

Where it is running

• The Herbst Clinic — Tucson, Arizona, United States
• Clinical and Translational Sciences Research Center (CATS) at the University of Arizona — Tucson, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.